Drug Trial Radar · NCT02127970
Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Last checked: Nov 19, 2026Latest source record: Sep 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
698
Actual
Start
Apr 18, 2014
Primary completion
Mar 11, 2015
Study completion Mar 11, 2015
Sponsor
- Lead sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plcIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected Gram-positive acute bacterial skin and skin structure infections (ABSSSI) at 48 -72 hours after initiation of treatment.
Conditions
- Abscess
- Wound Infection
- Surgical Site Infection
- Cellulitis
Interventions
DalbavancinDrug
Dalbavancin IV infusion over 30 minutes.
Dalbavancin-matching PlaceboDrug
Dalbavancin-matching placebo IV infusion over 30 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Were Clinical Responders 48-72 Hours After the Initiation of Study DrugTime frame: Up to 48-72 hours after the initiation of study drug
Locations
78 sites in 12 countries. Site status is shown where the registry gives one.
110
Montgomery, Alabama
103
Anaheim, California
117
Long Beach, California
106
Long Beach, California
118
Modesto, California
104
San Diego, California
113
San Diego, California
115
San Diego, California
116
San Diego, California
108
Stockton, California
105
Sylmar, California
112
Washington D.C., District of Columbia
107
Orlando, Florida
120
Saint Cloud, Florida
114
Augusta, Georgia
122
Columbus, Georgia
125
Savannah, Georgia
119
Eunice, Louisiana
101
Springfield, Massachusetts
109
Detroit, Michigan
121
Butte, Montana
123
Omaha, Nebraska
111
Toledo, Ohio
126
Franklin, Tennessee
127
Smyrna, Tennessee
802
Sofia, Bulgaria
800
Sofia, Bulgaria
801
Sofia, Bulgaria
200
Zagreb, Croatia
201
Zagreb, Croatia
253
Tallinn, Estonia
252
Tallinn, Estonia
251
Tartu, Estonia
302
Kutaisi, Georgia
303
Tbilisi, Georgia
300
Tbilisi, Georgia
301
Tbilisi, Georgia
352
Debrecen, Hungary
353
Kaposvár, Hungary
354
Pécs, Hungary
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.